Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | USP19 | O94966 | 1/20 | 0.34 |
| ▸ | USP14 | P54578 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580287 | 1.00 | RIPK1 (0.39) | RIPK1NSD2USP30PDK2USP19 | |
| SCHEMBL22210882 | 0.86 | USP30 (0.39) | RIPK1NSD2USP30DPP4FAP | |
| SCHEMBL22210942 | 0.86 | USP30 (0.39) | RIPK1NSD2USP30DPP4FAP | |
| SCHEMBL20580392 | 0.86 | USP30 (0.39) | RIPK1NSD2USP30DPP4FAP | |
| SCHEMBL20580398 | 0.85 | USP30 (0.38) | RIPK1NSD2USP30DPP4FAP | |
| SCHEMBL22210970 | 0.85 | USP30 (0.38) | RIPK1NSD2USP30DPP4FAP | |
| SCHEMBL18921471 | 0.85 | USP30 (0.38) | RIPK1NSD2USP30DPP4FAP | |
| SCHEMBL20580693 | 0.85 | USP30 (0.38) | RIPK1NSD2USP30PDK2DPP4 | |
| SCHEMBL22210917 | 0.85 | USP30 (0.38) | RIPK1NSD2USP30PDK2DPP4 | |
| SCHEMBL22210916 | 0.85 | USP30 (0.38) | RIPK1NSD2USP30PDK2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885NSD2 3603/4885USP30 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.